Dr Reddy’s Laboratories - Consolidated Results

• The company reported a Q3 net profit of Rs.1,209 crore, Revenue rose 4.4% YoY to Rs.8,753 crore, performing better than market expectation. Revenue rose 4% YoY to Rs.8,727 crore, EBITDA stood at Rs.2,049 crore, up 11% from the previous quarter but down from Rs.2,298 crore YoY, with margins at 23% versus 27% a year ago.
• Dr Reddy’s revenue in North America declined 12% y-o-y and 9% sequentially to Rs.2,964 crore, primarily due to higher price erosion and lower sales of Lenalidomide (Revlimid).
• Europe was up 20% y-o-y to Rs.1,448 crore, driven by continued traction in its nicotine replacement therapy (NRT) business, new product launches, and favourable forex. India business witnessed robust double-digit growth, with revenue increasing 19% y-o-y to Rs.1,603 crore. 

Results (Consolidated)                                                                              Rs cr.